177 related articles for article (PubMed ID: 9629873)
1. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
Hesketh PJ; Gralla RJ; du Bois A; Tonato M
Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
Grunberg SM; Osoba D; Hesketh PJ; Gralla RJ; Borjeson S; Rapoport BL; du Bois A; Tonato M
Support Care Cancer; 2005 Feb; 13(2):80-4. PubMed ID: 15599601
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
[TBL] [Abstract][Full Text] [Related]
4. [Methodology of the evaluation of antiemetics].
Bergmann JF
Bull Cancer; 1995 Dec; 82(12):1062-6. PubMed ID: 8745674
[TBL] [Abstract][Full Text] [Related]
5. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
6. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
7. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control.
Schnell FM
Oncologist; 2003; 8(2):187-98. PubMed ID: 12697943
[TBL] [Abstract][Full Text] [Related]
9. Delayed emesis following anticancer chemotherapy.
Kris MG; Roila F; De Mulder PH; Marty M
Support Care Cancer; 1998 May; 6(3):228-32. PubMed ID: 9629874
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
11. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice.
Hesketh PJ
Oncologist; 1999; 4(3):191-6. PubMed ID: 10394587
[TBL] [Abstract][Full Text] [Related]
12. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
14. Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh PJ; Kris MG; Grunberg SM; Beck T; Hainsworth JD; Harker G; Aapro MS; Gandara D; Lindley CM
J Clin Oncol; 1997 Jan; 15(1):103-9. PubMed ID: 8996130
[TBL] [Abstract][Full Text] [Related]
15. [The control of chemotherapy-induced nausea and vomiting].
Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
[TBL] [Abstract][Full Text] [Related]
16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
18. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
